• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
PXS
Click for more information
0.00% 8.5¢

PHARMAXIS LTD - Announcements

Currently unlisted. watchlist Created with Sketch. Add to my watchlist

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits

Announcements


Plus500
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW
TRADE NOW
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW

Filter Results
All Price Sensitive Only
search Created with Sketch. Search
search Created with Sketch. Search
PXS US FDA Convenes Advisory Committee for Bronchitol26/03/19
PXS Becoming a substantial holder05/03/19
PXS Ceasing to be a substantial holder04/03/19
PXS Boehringer Completes Enrollment of Phase 2A Trial in NASH25/02/19
PXS Pharmaxis Commences Phase 1 LOX Clinical TrialPRICE SENSITIVE22/02/19
PXS Half Yearly Report and AccountsPRICE SENSITIVE14/02/19
PXS Quarterly Shareholder Update - December 2018PRICE SENSITIVE30/01/19
PXS Appendix 4C - quarterlyPRICE SENSITIVE30/01/19
PXS Pharmaxis Announces LOXL2 Program Phase 2 ReadyPRICE SENSITIVE17/01/19
PXS PHARMAXIS ANNOUNCES RESUBMISSION OF BRONCHITOL NDA IN USAPRICE SENSITIVE20/12/18
PXS Pharmaxis Announces First Relaunch Sales of Aridol in USAPRICE SENSITIVE13/12/18
PXS Change in substantial holding27/11/18
PXS Appendix 3B - exercise of employee options26/11/18
PXS Final Director's Interest Notice22/11/18
PXS Change of Director's Interest Notice22/11/18
PXS Appendix 3B - Grant of options to CEO22/11/18
PXS Results of Meeting22/11/18
PXS Pharmaxis AGM - CEO PresentationPRICE SENSITIVE22/11/18
PXS Chairman's Address to ShareholdersPRICE SENSITIVE22/11/18
PXS Pharmaxis AGM - Withdrawal of Resolution22/11/18
PXS Investor Research Briefing Presentations20/11/18
PXS LOX Inhibitor Program for Pancreatic Cancer Phase 1 ReadyPRICE SENSITIVE20/11/18
PXS Pharmaxis Releases Positive Results of Phase 1 Clinical TriaPRICE SENSITIVE15/11/18
PXS Pharmaxis Investor Research Briefing15/11/18
PXS Quarterly Shareholder Update - September 201826/10/18
PXS Appendix 4C - quarterlyPRICE SENSITIVE26/10/18
PXS Copy of Corporate Governance Statement19/10/18
PXS Appendix 4G19/10/18
PXS Annual Report to shareholders19/10/18
PXS Notice of Annual General Meeting/Proxy Form19/10/18
PXS Updated Investor Presentation11/10/18
PXS Positive Phase 1 Results of Phase 1 Study - LOXL2 InhibitorPRICE SENSITIVE11/10/18
PXS Director Retirement04/10/18
PXS Change in substantial holding26/09/18
PXS Appendix 3B - exercise of employee options26/09/18
PXS Change in substantial holding25/09/18
PXS Change in substantial holding from AEF25/09/18
PXS Appendix 3B - exercise of 25,000 employee options21/09/18
PXS Change of Director's Interest Notice - Metters21/09/18
PXS Change of Director's Interest Notice - W Delaat21/09/18
PXS Change of Director's Interest Notice - Phillips21/09/18
PXS Change of Director's Interest Notice - McComas21/09/18
PXS Change of Director's Interest Notice - S Buckingham21/09/18
PXS Section 708A Notice21/09/18
PXS Appendix 3B - Placement Tranche 221/09/18
PXS Initial Director's Interest Notice - E Rayner18/09/18
PXS Director Appointment - Edward Rayner18/09/18
PXS Results of Meeting17/09/18
PXS Chairman's Introductory Comments to Shareholders17/09/18
PXS Investor Presentation28/08/18
PXS Notice of Extraordinary General Meeting/Proxy Form20/08/18
PXS Notice of initial substantial holder17/08/18
PXS Preliminary Final ReportPRICE SENSITIVE17/08/18
PXS Change in substantial holding16/08/18
PXS FDA Factory Approval and Relaunch of Aridol in US MarketPRICE SENSITIVE15/08/18
PXS Section 708A Notice14/08/18
PXS Appendix 3B - Placement Tranche 114/08/18
PXS Capital Raising PresentationPRICE SENSITIVE06/08/18
PXS Pharmaxis Announces A$24m PlacementPRICE SENSITIVE06/08/18
PXS Trading Halt Announcement - System UpgradePRICE SENSITIVE06/08/18
PXS Trading HaltPRICE SENSITIVE03/08/18
PXS Quarterly Shareholder Update - June 2018PRICE SENSITIVE27/07/18
PXS Appendix 4C - quarterlyPRICE SENSITIVE27/07/18
PXS Proposed Issue of Securities to Chief Executive Officer25/07/18
PXS Appendix 3B - Grant of Employee Options and Shares25/07/18
PXS Appendix 3B - Exercise of Employee Options25/07/18
PXS Appendix 3B - Exercise of Employee Options17/07/18
PXS Change of Director's Interest Notice - Expiring Options02/07/18
PXS LOXL2 Program Attracts Strong Partner Interest at BIO18PRICE SENSITIVE14/06/18
PXS Quarterly Shareholder Update - March 2018PRICE SENSITIVE30/04/18
PXS Appendix 4C - quarterlyPRICE SENSITIVE30/04/18
PXS Change in substantial holding05/04/18
PXS Change in substantial holding from AEF04/04/18
PXS Appendix 3B - Exercise of Employee Options08/03/18
PXS Half Yearly Report and AccountsPRICE SENSITIVE15/02/18
PXS Investor Presentation - 7 February 201807/02/18
PXS Investor Presentation - 30 January 201831/01/18
PXS Appendix 4C - quarterlyPRICE SENSITIVE29/01/18
PXS Quarterly Shareholder Update - December 201729/01/18
PXS Pharmaxis Earns A$15 Million Milestone PaymentPRICE SENSITIVE11/01/18
PXS New Australian PBS Listing for BrocnhitolPRICE SENSITIVE02/01/18
PXS Pharmaxis Acquires Control, Increases Stake in LOXL2 ProgramPRICE SENSITIVE14/12/17
PXS Appendix 3B - Grant of Employee Peformance Rights14/11/17
PXS Change of Director's Interest Notice - G Phillips14/11/17
PXS Results of Meeting14/11/17
PXS CEO Presentation to 2017 AGM13/11/17
PXS Chairman's Address to Shareholders13/11/17
PXS Quarterly Shareholder Update - September 201727/10/17
PXS Appendix 4C - quarterlyPRICE SENSITIVE27/10/17
PXS Investor Presentation - 23 October 201723/10/17
PXS Pharmaxis Strengthens Drug Discovery Capability19/10/17
PXS Copy of Corporate Governance Statement - 12 October 201712/10/17
PXS 2017 Appendix 4G - Key to Disclosures12/10/17
PXS Notice of 2017 Annual General Meeting/Proxy Form12/10/17
PXS 2017 Annual Report to Shareholders12/10/17
PXS Appendix 3B - Exercise of employee options09/10/17
PXS Investor Presentation08/09/17
PXS Interview with CEO - New Phase 2 Study by Boehringer08/09/17
PXS Boehringer Initiating Phase 2a Study Diabetic RetinopathyPRICE SENSITIVE08/09/17
PXS Antifibrotic LOXL2 Program Clears Preclinical DevelopmentPRICE SENSITIVE06/09/17
PXS US FDA Convenes Advisory Committee for Bronchitol
26/03/19
PXS Becoming a substantial holder
05/03/19
PXS Ceasing to be a substantial holder
04/03/19
PXS Boehringer Completes Enrollment of Phase 2A Trial in NASH
25/02/19
PXS Pharmaxis Commences Phase 1 LOX Clinical Trial
22/02/19PRICE SENSITIVE
PXS Half Yearly Report and Accounts
14/02/19PRICE SENSITIVE
PXS Quarterly Shareholder Update - December 2018
30/01/19PRICE SENSITIVE
PXS Appendix 4C - quarterly
30/01/19PRICE SENSITIVE
PXS Pharmaxis Announces LOXL2 Program Phase 2 Ready
17/01/19PRICE SENSITIVE
PXS PHARMAXIS ANNOUNCES RESUBMISSION OF BRONCHITOL NDA IN USA
20/12/18PRICE SENSITIVE
PXS Pharmaxis Announces First Relaunch Sales of Aridol in USA
13/12/18PRICE SENSITIVE
PXS Change in substantial holding
27/11/18
PXS Appendix 3B - exercise of employee options
26/11/18
PXS Final Director's Interest Notice
22/11/18
PXS Change of Director's Interest Notice
22/11/18
PXS Appendix 3B - Grant of options to CEO
22/11/18
PXS Results of Meeting
22/11/18
PXS Pharmaxis AGM - CEO Presentation
22/11/18PRICE SENSITIVE
PXS Chairman's Address to Shareholders
22/11/18PRICE SENSITIVE
PXS Pharmaxis AGM - Withdrawal of Resolution
22/11/18
PXS Investor Research Briefing Presentations
20/11/18
PXS LOX Inhibitor Program for Pancreatic Cancer Phase 1 Ready
20/11/18PRICE SENSITIVE
PXS Pharmaxis Releases Positive Results of Phase 1 Clinical Tria
15/11/18PRICE SENSITIVE
PXS Pharmaxis Investor Research Briefing
15/11/18
PXS Quarterly Shareholder Update - September 2018
26/10/18
PXS Appendix 4C - quarterly
26/10/18PRICE SENSITIVE
PXS Copy of Corporate Governance Statement
19/10/18
PXS Appendix 4G
19/10/18
PXS Annual Report to shareholders
19/10/18
PXS Notice of Annual General Meeting/Proxy Form
19/10/18
PXS Updated Investor Presentation
11/10/18
PXS Positive Phase 1 Results of Phase 1 Study - LOXL2 Inhibitor
11/10/18PRICE SENSITIVE
PXS Director Retirement
04/10/18
PXS Change in substantial holding
26/09/18
PXS Appendix 3B - exercise of employee options
26/09/18
PXS Change in substantial holding
25/09/18
PXS Change in substantial holding from AEF
25/09/18
PXS Appendix 3B - exercise of 25,000 employee options
21/09/18
PXS Change of Director's Interest Notice - Metters
21/09/18
PXS Change of Director's Interest Notice - W Delaat
21/09/18
PXS Change of Director's Interest Notice - Phillips
21/09/18
PXS Change of Director's Interest Notice - McComas
21/09/18
PXS Change of Director's Interest Notice - S Buckingham
21/09/18
PXS Section 708A Notice
21/09/18
PXS Appendix 3B - Placement Tranche 2
21/09/18
PXS Initial Director's Interest Notice - E Rayner
18/09/18
PXS Director Appointment - Edward Rayner
18/09/18
PXS Results of Meeting
17/09/18
PXS Chairman's Introductory Comments to Shareholders
17/09/18
PXS Investor Presentation
28/08/18
PXS Notice of Extraordinary General Meeting/Proxy Form
20/08/18
PXS Notice of initial substantial holder
17/08/18
PXS Preliminary Final Report
17/08/18PRICE SENSITIVE
PXS Change in substantial holding
16/08/18
PXS FDA Factory Approval and Relaunch of Aridol in US Market
15/08/18PRICE SENSITIVE
PXS Section 708A Notice
14/08/18
PXS Appendix 3B - Placement Tranche 1
14/08/18
PXS Capital Raising Presentation
06/08/18PRICE SENSITIVE
PXS Pharmaxis Announces A$24m Placement
06/08/18PRICE SENSITIVE
PXS Trading Halt Announcement - System Upgrade
06/08/18PRICE SENSITIVE
PXS Trading Halt
03/08/18PRICE SENSITIVE
PXS Quarterly Shareholder Update - June 2018
27/07/18PRICE SENSITIVE
PXS Appendix 4C - quarterly
27/07/18PRICE SENSITIVE
PXS Proposed Issue of Securities to Chief Executive Officer
25/07/18
PXS Appendix 3B - Grant of Employee Options and Shares
25/07/18
PXS Appendix 3B - Exercise of Employee Options
25/07/18
PXS Appendix 3B - Exercise of Employee Options
17/07/18
PXS Change of Director's Interest Notice - Expiring Options
02/07/18
PXS LOXL2 Program Attracts Strong Partner Interest at BIO18
14/06/18PRICE SENSITIVE
PXS Quarterly Shareholder Update - March 2018
30/04/18PRICE SENSITIVE
PXS Appendix 4C - quarterly
30/04/18PRICE SENSITIVE
PXS Change in substantial holding
05/04/18
PXS Change in substantial holding from AEF
04/04/18
PXS Appendix 3B - Exercise of Employee Options
08/03/18
PXS Half Yearly Report and Accounts
15/02/18PRICE SENSITIVE
PXS Investor Presentation - 7 February 2018
07/02/18
PXS Investor Presentation - 30 January 2018
31/01/18
PXS Appendix 4C - quarterly
29/01/18PRICE SENSITIVE
PXS Quarterly Shareholder Update - December 2017
29/01/18
PXS Pharmaxis Earns A$15 Million Milestone Payment
11/01/18PRICE SENSITIVE
PXS New Australian PBS Listing for Brocnhitol
02/01/18PRICE SENSITIVE
PXS Pharmaxis Acquires Control, Increases Stake in LOXL2 Program
14/12/17PRICE SENSITIVE
PXS Appendix 3B - Grant of Employee Peformance Rights
14/11/17
PXS Change of Director's Interest Notice - G Phillips
14/11/17
PXS Results of Meeting
14/11/17
PXS CEO Presentation to 2017 AGM
13/11/17
PXS Chairman's Address to Shareholders
13/11/17
PXS Quarterly Shareholder Update - September 2017
27/10/17
PXS Appendix 4C - quarterly
27/10/17PRICE SENSITIVE
PXS Investor Presentation - 23 October 2017
23/10/17
PXS Pharmaxis Strengthens Drug Discovery Capability
19/10/17
PXS Copy of Corporate Governance Statement - 12 October 2017
12/10/17
PXS 2017 Appendix 4G - Key to Disclosures
12/10/17
PXS Notice of 2017 Annual General Meeting/Proxy Form
12/10/17
PXS 2017 Annual Report to Shareholders
12/10/17
PXS Appendix 3B - Exercise of employee options
09/10/17
PXS Investor Presentation
08/09/17
PXS Interview with CEO - New Phase 2 Study by Boehringer
08/09/17
PXS Boehringer Initiating Phase 2a Study Diabetic Retinopathy
08/09/17PRICE SENSITIVE
PXS Antifibrotic LOXL2 Program Clears Preclinical Development
06/09/17PRICE SENSITIVE
refresh Created with Sketch. REFRESH
 

Top Stories

Week 46 Wrap: Copper hits 2mth low as Trump threatens net zero pace; US rally fades; HotCopper’s picks

Copper prices slump; Trump Wall Street rally fades; US health stocks dip on RFK appointment – and much more.
CuFe sells its Crossroads gold royalty to Northern Star for $4M cash; says better than waiting for mine launch CuFe Ltd (ASX:CUF) has decided not to wait around for Northern Star's Crossroads mine to get up and running, selling its $4M royalty right.
To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels Put simply: if 3D Printing is a gold rush, Amaero is selling shovels. Or maybe it's more like sneakers in an arms race.
Banshee's historic trenches prove rich in antimony and gold for GDM Great Divide Mining Ltd has found high-grade antimony and gold through geochemical sampling at its Banshee prospect in Queensland
HotCopper Highlights: Your most watched stocks for Week 46, 2024 What you - HotCopper users - were most interested in viewing and discussing this week (Week 46 of the year!)
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.